Advertisement

Overcoming Lung Clearance Mechanisms for Controlled Release Drug Delivery

  • Ibrahim M. El-SherbinyEmail author
  • Diana G. Villanueva
  • Dea Herrera
  • Hugh D. C. Smyth
Chapter
Part of the Advances in Delivery Science and Technology book series (ADST)

Abstract

The lung anatomy and physiology is well adapted to handle exogenous aerosols and rapidly process them for clearance. Only in a few circumstances in nature are these defenses breached, with dire consequences, as in the case of asbestos. For controlled drug delivery to the lung, however, the goal is to slow or evade these clearance mechanisms using biocompatible systems that elicit no inflammatory response but allow modulated drug release. In this chapter, we introduce briefly the principles of the lung clearance mechanisms including mucociliary, absorptive, phagocytic, and metabolic clearance. Then, we review the literature and present the current and emerging approaches to effectively control release in the pulmonary system. These approaches include manipulating drug deposition site, modifying drug absorption rates, eluding macrophage uptake, and controlling degradation of the therapeutic agent.

Keywords

Avoiding Controlled delivery Clearance Lung Phagocytosis PEGylation Pulmonary Sustained release 

References

  1. 1.
    Adjei A, Hui J, Finely R et al (1994) Pulmonary bioavailability of leuprolide acetate following multiple dosing to beagle dogs: some pharmacokinetic and preclinical issues. J Pharm Sci 107:57–66Google Scholar
  2. 2.
    Adjei AL, Carrigan PJ (1992) Pulmonary bioavailability of LH-RH analogs: some pharmaceutical guidelines. J Biopharm Sci 3:247–254Google Scholar
  3. 3.
    Ahsan F, Rivas IP, Khan MA, Súarez-Torres AI (2002) Targeting to macrophages: role of physicochemical properties of particulate carriers–liposomes and microspheres on the phagocytosis by macrophages. J Control Release 79:29–40PubMedGoogle Scholar
  4. 4.
    Arppe J, Vidgren M, Waldrep JC (1998) Pulmonary pharmacokinetics of cyclosporin A liposomes. Int J Pharm 161:205–214Google Scholar
  5. 5.
    Ben-Jebria A, Chen D, Eskew ML et al (1999) Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs. Pharm Res 16:555–561PubMedGoogle Scholar
  6. 6.
    Beyerle A, Merkel O, Stoeger T, Kissel T (2010) PEGylation affects cytotoxicity and cell-compatibility of poly(ethylene imine) for lung application: structure–function relationships. Toxicol Appl Pharmacol 242:146–154PubMedGoogle Scholar
  7. 7.
    Bhat M (2002) Development of a novel spray-drying technique to produce particles for aerosol delivery. In: Dalby R, Byron PR, Peart J, Farr SJ (eds) Respiratory drug delivery XIII. Davis Horwood International Publishing, Raleigh, NC, pp 427–429Google Scholar
  8. 8.
    Bittner B, Kissel T (1999) Ultrasonic atomization for spray drying: a versatile technique for the preparation of protein loaded biodegradable microspheres. J Microencapsul 16:325–341PubMedGoogle Scholar
  9. 9.
    Bot AI, Tarara TE, Smith DJ et al (2000) Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. Pharm Res 17:275–283PubMedGoogle Scholar
  10. 10.
    Boucher RC (2003) Regulation of airway surface liquid volume by human airway epithelia. Eur J Physiol 445:495–498Google Scholar
  11. 11.
    Boucher RC, Stutts MJ, Gatzy JT (1981) Regional differences in bioelectric properties and ion flow in excised canine airways. J Appl Physiol 51:706–714PubMedGoogle Scholar
  12. 12.
    Byron PR (1993) Physicochemical effects on lung disposition of pharmaceutical aerosols. Aerosol Sci Tech 18:223–229Google Scholar
  13. 13.
    Cannon GJ, Swanson JA (1992) The macrophage capacity for phagocytosis. J Cell Sci 101:907–913PubMedGoogle Scholar
  14. 14.
    Canonico AE, Plitman JD, Conary JT et al (1994) No lung toxicity after repeated aerosol or intravenous delivery of plasmid cationic liposome complexes. J Appl Physiol 77:415–419PubMedGoogle Scholar
  15. 15.
    Champion JA, Mitragotri S (2006) Role of target geometry in phagocytosis. PNAS 103:4930–4934PubMedGoogle Scholar
  16. 16.
    Cheng YS, Yazzie D, Gao J et al (2003) Particle characteristics and lung deposition patterns in a human airway replica of a dry powder formulation of polylactic acid produced using supercritical fluid technology. J Aerosol Med 16:65–73PubMedGoogle Scholar
  17. 17.
    Chow AH, Tong HH, Chattopadhyay P et al (2007) Particle engineering for pulmonary drug delivery. Pharma Res 24:411–432Google Scholar
  18. 18.
    Codrons V, Vanderbist F, Ucakar B et al (2004) Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1–34) from rat lungs. J Pharm Sci 93:1241–1252PubMedGoogle Scholar
  19. 19.
    Crommelin D, Schreier H (1994) Liposomes. In: Kreuter J (ed) Colloidal drug delivery systems. Marcel Dekker, New York, pp 73–190Google Scholar
  20. 20.
    Derrien D, Midoux P, Petit C et al (1989) Muramyl dipeptide bound to poly-L-lysine substituted with mannose and gluconoyl residues as macrophage activators. Glycoconj J 6:241–255PubMedGoogle Scholar
  21. 21.
    Desai T, Hancock REW, Finaly WH (2002) A facile method of delivery of liposomes by nebulization. J Control Release 84:69–78PubMedGoogle Scholar
  22. 22.
    Devereux TR, Domin BA, Philpot RM (1989) Xenobiotic metabolism by isolated pulmonary cells. Pharmacol Ther 41:243–256PubMedGoogle Scholar
  23. 23.
    Dhiman N, Khuller GK (1998) Protective efficacy of mycobacterial 71-kDa cell wall associated protein using poly (DL-lactide-co-glycolide) microparticles as carrier vehicles. FEMS Immunol Med Microbiol 21:19–28PubMedGoogle Scholar
  24. 24.
    Eastman S, Tousignant JD, Lukason MJ et al (1997) Optimisation of formulations and conditions for the aerosol delivery of functional cationic lipids: DNA complex. Hum Gene Ther 8:313–322PubMedGoogle Scholar
  25. 25.
    Edsman K, Hägerström H (2005) Pharmaceutical applications of mucoadhesion for the non-oral routes. J Pharm Pharmacol 57:3–22PubMedGoogle Scholar
  26. 26.
    Edwards DA, Ben-Jebria A, Langer R (1998) Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol 85:379–385PubMedGoogle Scholar
  27. 27.
    Edwards DA, Hanes J, Caponetti G et al (1997) Large porous particles for pulmonary drug delivery. Science 276:1868–1871PubMedGoogle Scholar
  28. 28.
    Ehrhardt C, Fiegel J, Fuchs S et al (2002) Drug absorption by the respiratory mucosa: cell culture models and particulate drug carriers. J Aerosol Med 15:131–139PubMedGoogle Scholar
  29. 29.
    El-Sherbiny IM, McGill S, Smyth HDC (2009) Swellable microparticles as carriers for sustained pulmonary drug delivery. J Pharm Sci 99:2343–2356Google Scholar
  30. 30.
    Esmailpour NH, Hogger P, Rabe KF et al (1997) Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J 10:1496–1499PubMedGoogle Scholar
  31. 31.
    Evora C, Soriano I, Rogers RA et al (1998) Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. J Control Release 51:143–152PubMedGoogle Scholar
  32. 32.
    Fiegel J, Ehrhardt C, Schaefer UF, Lehr CM, Hanes J (2003) Large porous particle impingement on lung epithelial cell monolayers-toward improved particle characterization in the lung. Pharm Res 20:788–796PubMedGoogle Scholar
  33. 33.
    Fielding R, Ahra RM (1992) Factors affecting the release rate of terbutaline from liposome formulations after intratracheal instillation in the guinea pig. Pharm Res 9:220–223PubMedGoogle Scholar
  34. 34.
    Gibbons AM, McElvaney NJ, Taggart CC, Cryan SA (2009) Delivery of rSLPI in a liposomal carrier for inhalation provides protection against cathepsin L degradation. J Microencapsul 26:513–522PubMedGoogle Scholar
  35. 35.
    Gregoriadis G (1984) Liposome technology. CRC, Boca RatonGoogle Scholar
  36. 36.
    Grenha A, Grainger CI, Dailey LA et al (2007) Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro. Eur J Pharm Sci 31:73–84PubMedGoogle Scholar
  37. 37.
    Gudapaty SR, Liener IE, Hoidal JR et al (1985) The prevention of elastase-induced emphysema in hamsters by intratracheal ad-ministration of a synthetic elastase inhibitor bound to albumin microspheres. Am Rev Respir Dis 132:159–163PubMedGoogle Scholar
  38. 38.
    Harris JM, Chess RB (2003) Effect of PEGylation on pharmaceuticals. Nat Rev Drug Discov 2:214–221PubMedGoogle Scholar
  39. 39.
    Harvey RJ, Schlosser RJ (2009) Local drug delivery. Otolaryngol Clin North Am 42:829–845PubMedGoogle Scholar
  40. 40.
    Heyder J, Gebhart J, Rudolf G et al (1896) Deposition of particles in the human respiratory tract in the size range 0.005-15 μm. J Aerosol Sci 17:811–825Google Scholar
  41. 41.
    Heydet J, Rudolf G (1984) Mathematical models of particle deposition in the human respiratory tract. J Aerosol Sci 17:697–707Google Scholar
  42. 42.
    Hogg JC (1985) Response of the lung to inhaled particles. Med J Aust 142:675–678PubMedGoogle Scholar
  43. 43.
    Houtmeyers E, Gosselink R, Gayan-Ramirez G et al (1999) Regulation of mucociliary clearance in health and disease. Eur Respir J 13:1177–1188PubMedGoogle Scholar
  44. 44.
    Hutchinson FG, Furr BJ (1989) Biodegradable polymers for controlled release of peptides and proteins. Horiz Biochem Biophys 9:111–129PubMedGoogle Scholar
  45. 45.
    Johnson M (1996) Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol 97:169–176PubMedGoogle Scholar
  46. 46.
    Joshi M, Misra A (2001) Dry powder inhalation of liposomal Ketotifen fumarate formulation and characterisation. Int J Pharm 223:15–27PubMedGoogle Scholar
  47. 47.
    Kaplan J, Ward DM (1990) Movement of receptors and ligands through the endocytic apparatus in alveolar macrophages. Am J Physiol 258:L263–L270PubMedGoogle Scholar
  48. 48.
    Kawaguchi H, Koiwai N, Ohtsuka Y et al (1986) Phagocytosis of latex particles by leucocytes. Dependence of phagocytosis on the size and surface potential of particles. Biomaterials 7:61–66PubMedGoogle Scholar
  49. 49.
    Kawashima Y, Yamamoto H, Takeuchi H, Fujioka S, Hino T (1999) Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J Control Release 62:279–287PubMedGoogle Scholar
  50. 50.
    Kim JC, Kim JD (2001) Preparation by spray-drying of amphotericin B phospholipid composite particles and their anticellular activity. Drug Deliv 8:143–147PubMedGoogle Scholar
  51. 51.
    Kips JC, Pauwels RA (2001) Long acting inhaled β2-agonist therapy in asthma. Am J Respir Crit Care Med 164:923–932PubMedGoogle Scholar
  52. 52.
    Klonne DR, Dodd DE, Losco PE et al (1989) Two-week aerosol inhalation study on polyethylene glycol (PEG) 3350 in F-344 rats. Drug Chem Toxicol 12:39–48PubMedGoogle Scholar
  53. 53.
    Koushik K, Dhanda DS, Cheruvu NPS, Kompella UB (2004) Pulmonary Delivery of Deslorelin: Large-porous PLGA particles and HPBCD complexes. Pharm Res 21:1119–1126PubMedGoogle Scholar
  54. 54.
    Koval M, Preiter K, Adled C et al (1998) Size of IgG-opsonized particles determines macrophage response during internalization. Exp Cell Res 242:265–273PubMedGoogle Scholar
  55. 55.
    Krenis LJ, Strauss B (1961) Effect of size and concentration of latex particles on respiration of human blood leucocytes. Proc Soc Exp Med 107:748–750Google Scholar
  56. 56.
    Kumar N, Chaubal M, Domb A et al (2003) Controlled release technology. In: Encyclopedia of polymer science and technology, vol. 5. Wiley, Hoboken, p 697.Google Scholar
  57. 57.
    Kumar RMNV (2000) A review of chitin and chitosan applications. React Funct Polym 46:1–27Google Scholar
  58. 58.
    Lai Y, Mehta RC, Thacker AA et al (1993) Sustained bronchodilation with isoproterenol poly(glycolide-co-lactide) microspheres. Pharm Res 10:119–125PubMedGoogle Scholar
  59. 59.
    Lasic D (1997) Liposomes in gene delivery. CRC, Boca RatonGoogle Scholar
  60. 60.
    Lee SL, Adams WP, Li BV et al (2009) In vitro considerations to support bioequivalence of locally acting drug in dry powder inhalers for lung diseases. AAPS J 11:414–423PubMedGoogle Scholar
  61. 61.
    Letsou GV, Safi HJ, Reardon MJ et al (1999) Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression. Ann Thorac Surg 68:2044–2048PubMedGoogle Scholar
  62. 62.
    Liang WW, Shi X, Deshpande D et al (1996) Oligonucleotide targeting to alveolar macrophages by mannose receptormediated endocytosis. Biochim Biophys Acta 1279:227–234PubMedGoogle Scholar
  63. 63.
    Lombry C, Edwards DA, Preat V et al (2004) Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules. Am J Physiol Lung Cell Mol Physiol 286:L1002–L1008PubMedGoogle Scholar
  64. 64.
    Mall MA (2008) Role of the cilia, mucus, and airway surface liquid in mucociliary dysfunction: lessons from mouse models. J Aerosol Med Pulm Drug Deliv 21:12–24Google Scholar
  65. 65.
    Martonen T, Smyth HDC, Isacs K et al (2005) Issues in drug delivery: dry powder inhaler performance and lung deposition. Respir Care 50:1228–1252PubMedGoogle Scholar
  66. 66.
    Mathias NR, Hussainn MA (2010) Non-invasive systemic drug delivery: developability considerations for alternate routes of administration. J Pharm Sci 99:1–20PubMedGoogle Scholar
  67. 67.
    Matsui H, Randell SH, Peretti SW et al (1998) Coordinated cleareance of periciliary liquid and mucus from airway surfaces. J Clin Invest 102:1125–1132PubMedGoogle Scholar
  68. 68.
    McCluskie MJ, Chu Y, Xia JL et al (1998) Direct gene transfer to the respiratory tract of mice with pure plasmid and lipid-formulated DNA. Antisense Nucleic Acid Drug Dev 8:401–414PubMedGoogle Scholar
  69. 69.
    McLachlan G, Davidson DJ, Stevenson BJ et al (1995) Evaluation in vitro and in vivo of cationic liposome-expression construct complexes for cystic fibrosis gene therapy. Gene Ther 2:614–622PubMedGoogle Scholar
  70. 70.
    Meers P, Neville M, Malinin V et al (2008) Biofilm preparation, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aerudinosa ling infections. J Antimicrob Chemother 61:859–868PubMedGoogle Scholar
  71. 71.
    Miller-Larsson A (2004) Concluding clinical synergism from preclinical study data. Respir Drug Deliv 1:87–98Google Scholar
  72. 72.
    Montgomery AB, Pitlick WH, Nardella P et al (2000) Sputum concentrations and systemic pharmacokinetics of aerosolized tobramycin (tobi) in diseased lungs. Respir Drug Deliv 1:19–24Google Scholar
  73. 73.
    Musante CJ, Schroeter JD, Rosati JA et al (2002) Factors affecting the deposition of inhaled porous drug particles. J Pharm Sci 91:1590–1600PubMedGoogle Scholar
  74. 74.
    Niven R (2003) Modulated drug therapy with inhalation aerosols. In: Hickey AJ (ed) Pharmaceutical inhalation aerosols technology. Marcel Dekker, New York, pp 551–570Google Scholar
  75. 75.
    Niven R, Carvajal TM, Schreier H (1992) Nebulization of liposomes. III. The effects of operating conditions and local environment. Pharm Res 9:515–520PubMedGoogle Scholar
  76. 76.
    Niven R, Schreier H (1990) Nebulization of liposomes. I. Effects of lipid composition. Pharm Res 7:1127–1133PubMedGoogle Scholar
  77. 77.
    Niven R, Speer M, Schreier H (1991) Nebulization of liposomes. II. The effects of size and modeling of solute release profiles. Pharm Res 8:217–221PubMedGoogle Scholar
  78. 78.
    Niven RW, Whitcomb KL, Shaner L et al (1995) The pulmonary absorption of aerosolized and intratracheally instilled rhG-CSF and monoPEGylated rhG-CSF. Pharm Res 12:1343–1349PubMedGoogle Scholar
  79. 79.
    Oberdorster G (2001) Pulmonary effects of inhaled ultrafine particles. Int Arch Occup Environ Health 74:1–8PubMedGoogle Scholar
  80. 80.
    Olsson T, Svensson LA (1984) New lipophilic terbutaline ester prodrugs with long effect duration. Pharm Res 3:19–23Google Scholar
  81. 81.
    Park K (1997) Controlled drug delivery: challenges and strategies. American Chemical Society, Washington, 629Google Scholar
  82. 82.
    Patton JS (1996) Mechanisms of macromolecule absorption by the lungs. Adv Drug Del Rev 19:3–36Google Scholar
  83. 83.
    Patton JS, Byron PR (2007) Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 6:67–74PubMedGoogle Scholar
  84. 84.
    Plowman S, Langner E, Blair J (2002) Elucidation of insulin release mechanism from OED microparticles using ATR-FTIR. In: Dalby R, Byron PR, Peart J, Farr SJ (eds) Respiratory drug delivery VIII. Davis Horwood International Publishing, Raleigh, pp 423–426Google Scholar
  85. 85.
    Poyner EA, Alpar HO, Almeida AJ et al (1995) A comparative study on the pulmonary delivery of tobramycin encapsulated into liposomes and PLA microspheres following intravenous and endotracheal delivery. J Control Release 35:41–48Google Scholar
  86. 86.
    Robbins JC, Lam MH, Tripp CS et al (1981) Synthetic glycopeptide substrates for receptor-mediated endocytosis by macrophages. Proc Natl Acad Sci USA 78:7294–7298PubMedGoogle Scholar
  87. 87.
    Rudt S, Muller RH (1992) In vitro phagocytosis assay of nano- and microparticles by ­chemiluminescence. III. Uptake of differently sized surface-modified particles and its correlation to particle properties and in vivo distribution. Eur J Pharm Sci 1:31–39Google Scholar
  88. 88.
    Sakagami M, Kinoshita W, Sakon K et al (2002) Mucoadhesive beclomethasone microspheres for powder inhalation: their pharmacokinetics and pharmacodynamics evaluation. J Control Release 80:207–218PubMedGoogle Scholar
  89. 89.
    Sally-Ann C (2005) Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J 7:E20–E41Google Scholar
  90. 90.
    Scheuch G, Siekmeier R (2007) Novel approacches to enhance pulmonary delivery of proteins and peptides. J Physiol Pharmacol 58:615–625PubMedGoogle Scholar
  91. 91.
    Schreier H, Mobley WC, Concessio N et al (1994) Formulation and in vitro performance of liposome powder aerosols. STP Pharma Sci 4:38–44Google Scholar
  92. 92.
    Seville PC, Kellaway IW, Birchall JC (2002) Preparation of dry powder dispersions for non-viral gene delivery by freeze-drying and spray-drying. J Gene Med 4:428–437PubMedGoogle Scholar
  93. 93.
    Sharma R, Saxena D, Dwivedi AK, Misra A (2001) Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res 18:1405–1410PubMedGoogle Scholar
  94. 94.
    Sibille Y, Reynolds HY (1990) Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis 141:471–501PubMedGoogle Scholar
  95. 95.
    Siekmeier R, Scheuch G (2008) Systemic treatment by inhalation of macromolecules-principles, problems, and examples. J Physiol Pharmacol 59:53–79PubMedGoogle Scholar
  96. 96.
    Simon SI, Schmid-Chongeing GW (1988) Biophysical aspects of microsphere engulfment by human neutrophils. Biophys J 53:163–173PubMedGoogle Scholar
  97. 97.
    Skalko-Basnet N, Pavelic Z, Becirevic-Lacan M (2000) Liposomes containing drug and cyclodextrin prepared by the one-step spray-drying method. Drug Dev Ind Pharm 26:1279–1284PubMedGoogle Scholar
  98. 98.
    Smyth HDC, Hickey AJ (2005) Carriers in drug powder delivery: implications for inhalation system design. Am J Drug Deliv 3:117–132Google Scholar
  99. 99.
    Standard W, O’callaghan C (2006) Ciliary function and the role of cilia in clearance. J Aerosol Med 19:110–115Google Scholar
  100. 100.
    Stone KC, Mercer RR, Gehr P et al (1992) Allometric relationships of cell numbers and size in the mammalian lung. Am J Respir Cell Mol Biol 6:235–243PubMedGoogle Scholar
  101. 101.
    Stribling R, Brunette E, Liggitt D et al (1992) Aerosol gene delivery in vivo. Proc Natl Acad Sci USA 89:11277–11281PubMedGoogle Scholar
  102. 102.
    Suarez S, Gonzalez-Rothi RJ, Schreier H, Hochhaus G (1998) Effect of dose and release rate on pulmonary targeting of liposomal triamcinolone acetonide phosphate. Pharm Res 15:461–465PubMedGoogle Scholar
  103. 103.
    Suarez S, Hickey AJ (2000) Drug properties affecting aerosol behavior. Respir Care 45:652–666PubMedGoogle Scholar
  104. 104.
    Suarez S, O’Hara P, Kazantseva M et al (2001) Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J Antimicrob Chemother 48:431–434PubMedGoogle Scholar
  105. 105.
    Suarez S, O’Hara P, Kazantseva M et al (2001) Respirable PLGA microspheres containing rifampicin for the treatment of tuber-culosis: screening in an infectious disease model. Pharm Res 18:1315–1319PubMedGoogle Scholar
  106. 106.
    Surendrakumar K, Martyn GP, Hodgers ECM et al (2003) Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J Control Release 91:385–394PubMedGoogle Scholar
  107. 107.
    Suzuki Y, Yamaguchi T (1993) Effects of hyaluronic acid on macrophage phagocytosis and active oxygen release. Agents Actions 38:32–37PubMedGoogle Scholar
  108. 108.
    Tabata Y, Ikada Y (1988) Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials 9:356–362PubMedGoogle Scholar
  109. 109.
    Takeuchi H, Yamamoto H, Kawashima Y (2001) Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev 47:39–54PubMedGoogle Scholar
  110. 110.
    Talton J, Fitz-Gerald J, Singh R et al (2000) Nano-thin coating for improved lung targeting of glucocorticoid dry powders: in-vitro and in-vivo characteristics. In: Dalby RN, Byron PR, Farr SJ et al (eds) Respiratory drug delivery VII. Serentec Press, Raleigh, pp 67–74Google Scholar
  111. 111.
    Telko MJ, Hickey AJ (2005) Dry powder inhaler formulation. Respir Care 50:1209–1227PubMedGoogle Scholar
  112. 112.
    Tietze C, Schlesinger P, Stahl P (1982) Mannose-specific endocytosis receptor of alveolar macrophages: demonstration of two functionally distinct intracellular pools of receptor and their roles in receptor recycling. J Cell Biol 92:417–424PubMedGoogle Scholar
  113. 113.
    Traini D, Young PM (2009) Delivery of antibiotics to the respiratory tract: an update. Expert Opin Drug Deliv 6:897–905PubMedGoogle Scholar
  114. 114.
    Tsapis N, Bennett D, Jackson B et al (2002) Trojan particles: large porous carriers of ­nanoparticles for drug delivery. PNAS 99:12001–12005PubMedGoogle Scholar
  115. 115.
    Tsifansky MD, Yeo Y, Evgenov OV et al (2008) Microparticles for inhalational delivery of antipseudomonal antibiotics. AAPS J 10:254–260PubMedGoogle Scholar
  116. 116.
    Tsutsumi Y, Kihira T, Tsunoda S et al (1995) Molecular design of hybrid tumour necrosis factor alfa with polyethylene glycol increases its anti-tumor potency. Br J Cancer 71:963–968PubMedGoogle Scholar
  117. 117.
    Tsutsumi Y, Tsunoda S, Kamada H et al (1997) PEGylation of interleukin-6 effectively increases its thrombopoietic potency. Thromb Haemost 77:168–173PubMedGoogle Scholar
  118. 118.
    Usami OS, Biddiscombe MF, Underwood RS et al (2004) Characterization of the generation of radiolabeled monodisperse albuterol particles using the spinning-top aerosol generator. J Nucl Med 45:69–73Google Scholar
  119. 119.
    Venbever R, Ben-Jebria A, Mintzes JD et al (1999) sustained-release of insulin from insoluble inhaled particles. Drug Dev Res 48:178–185Google Scholar
  120. 120.
    Vyas SP, Kannan ME, Jain S, Mishra V et al (2004) Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int J Pharm 269:37–49PubMedGoogle Scholar
  121. 121.
    Weibel ER (1963) Morphometry of the human lung. Academic, New YorkGoogle Scholar
  122. 122.
    Widdicombe JH (2002) Regulation of the depth and composition of airway surface liquid. J Anat 201:313–318PubMedGoogle Scholar
  123. 123.
    Yanga Y, Bajajc N, Xua P, Ohnd K et al (2009) Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials 30:1947–1953Google Scholar
  124. 124.
    Zanen P, Go LT, Lammers JWJ (1994) The optimal particle size for β-Adrenergic aerosols in mild asthmatics. Int J Pharm 107:211–217Google Scholar
  125. 125.
    Zeng X, Martin CG, Marriott C (1995) The controlled delivery of drugs to the lung. Int J Pharm 124:149–164Google Scholar
  126. 126.
    Zou Y, Zong G, Ling YH, Perez-Soler R (2000) Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer. Cancer Gene Ther 7:683–696PubMedGoogle Scholar
  127. 127.
    Algranati NE, Sy S, Modi M (1999) A branched methoxy 40 KDA polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon alpha-2a (peginterferon) and may explain its enhanced efficacy in chronic hepatitis C (CHC). Hepatology 30: 190APubMedGoogle Scholar

Copyright information

© Controlled Release Society 2011

Authors and Affiliations

  • Ibrahim M. El-Sherbiny
    • 1
    • 2
    Email author
  • Diana G. Villanueva
  • Dea Herrera
  • Hugh D. C. Smyth
  1. 1.College of PharmacyUniversity of TexasAustinUSA
  2. 2.Mansoura UniversityMansouraEgypt

Personalised recommendations